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Abstract: A new anthracene derivative, 3-hydroxy-1-keto-3-methyl-8-methoxy-1,2,3, 
4-tetrahydro-benz[α]anthracene, was isolated from the marine strain Streptomyces sp. W007, 
and its structure was established by spectroscopic analysis including mass spectra,   
1D- and 2D-NMR (
1H–
1H COSY, HMBC, HSQC and NOESY) experiments. 3-hydroxy-1-
keto-3-methyl-8-methoxy-1,2,3,4-tetrahydro-benz[α]anthracene showed cytotoxicity against 
human lung adenocarcinoma cell line A549. 
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1. Introduction 
Natural products remain either the source or inspiration for a significant proportion of the new 
small-molecule chemical entities introduced as drugs [1]. Microbial natural products are an important 
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source of both existing and new drugs [2]. Among the producers of commercially important 
metabolites, actinomycetes have proven to be a proliﬁc source with a surprisingly small group of taxa 
accounting for the vast majority of compounds. Secondary metabolites produced by actinomycetes 
possess a wide range of biological activities [3–7], and the vast majority of these compounds are 
derived from the single genus Streptomyces [8].  
Streptomyces species are distributed widely in marine habitats and are of commercial interest due to 
their unique capacity to produce novel metabolites. Our group has done research on novel natural 
products of marine Streptomyces species with potential antitumor activity for 12 years [9–12]. As part 
of this work, in our screening of marine Streptomyces isolates for more active secondary metabolites, a 
new anthracene derivative, 3-hydroxy-1-keto-3-methyl-8-methoxy-1,2,3,4-tetrahydro-benz[α]anthracene 
(compound 1) was obtained from the fermentation broth of marine Streptomyces sp. W007 for the first 
time. The structure of compound 1 was determined by LC-MS, 
1H, 
13C and 2D NMR spectroscopy and 
by comparison of the NMR data with other anthraquinone compounds, the cytotoxicities of compound 1 
against human leukemic cells line HL-60, human lung adenocarcinoma cell line A549 and human 
hepatoma cell line BEL-7402 were studied, the details of structure and cytotoxicities of compound 1 
are presented here. 
2. Results and Discussion 
2.1. Structure Analysis of Compound 1 
Compound 1 (Figure 1, Table 1) was obtained as yellow powder and showed a quasi-molecular ion 
[M + H]
+ at m/z 307 in the LC-MS, which was consistent with the molecular formula C20H18O3  
(calcd for 306.3551), and required 12 degrees of unsaturation. Its 
1H NMR spectrum exhibited an 
aliphatic methyl singlet at δH 1.46 (3H, s), one methoxy group at δH 4.09 (3H, s), two methylene 
signals at δH 3.35 (2H, dd, 15.0, 20.0 Hz) and δ 2.97 (2H, dd, 10, 15 Hz) and 7 aromatic proton signals 
at δH 10.10 (1H, s), 8.78 (1H, s), 8.26 (1H, d, 8.6 Hz), 7.65 (1H, d, 8.25 Hz), 7.45 (1H, t, 8.25, 7.45 Hz), 
7.37 (1H, d, 8.6 Hz), 6.89 (1H, d, 7.55 Hz).  
Figure 1. ( A) Structure of compound 1; and (B) Selected 
1H–
1H COSY, HMBC and 
NOESY correlations for compound 1. 
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Table 1. 
1H and 
13C NMR data of compound 1 in CDCl3 (500 MHz). 
Position d  (J in Hz)  δC 
1   198.76 
2  2.97 (2H, dd, 10, 15)  54.28 
3   70.55 
4  3.35 (2H, dd, 15.0, 20.0)  45.41 
4a   145.61 
5  7.37 (1H, d, 8.6)  127.37 
6  8.26 (1H, d, 8.6)  135.19 
6a   130.69 
7  8.78 (1H, s)  121.52 
7a   124.29 
8   155.38 
9  6.89 (1H, d, 7.55)  102.5 
10  7.45 (1H, t, 8.25, 7.45)  126.35 
11  7.65 (1H, d, 8.25)  121.13 
11a   134.54 
12  10.10 (1H, s)  125.17 
12a   128.74 
12b   125.46 
13  1.46 (3H, s)  28.47 
14  4.09 (3H, s)  55.10 
The 
13C NMR, DEPT135 and HMBC spectra of compound 1 displayed two methyl resonances  
at δC 28.47 (C-13, 1-Me), 55.10 (C-14), two methylenes at δC 45.41 (C-4), 54.28 (C-2), methines  
at  δC 135.19 (C-6), 127.37 (C-5), 102.5 (C-9), 125.17 (C-12), 121.52 (C-7), 121.13 (C-11),   
126.35 (C-10), quaternary carbons at δC 155.38 (C-8), 145.61 (C-4a), 134.54 (C-11a), 130.69 (C-6a), 
128.74 (C-12a), 125.46 (C-12b), 124.29 (C-7a,), 70.55 (C-3), in addition to one carbonyl at   
δC 198.76 (C-1). By detailed comparison of the 
1H and 
13C NMR data of compound 1 with   
1,4,8,10-tetramethoxyanthracene-2-carbaldehyde [13], the similar NMR data of the aromatic moieties 
conﬁrmed that compound 1 has the anthracene skeleton. Because compound 1 required 12 degrees of 
unsaturation, there is a six-carbon ring next to the anthracene skeleton. In the NOESY spectrum,  
the proton at δH 3.35 (H-4) showed a correlation with the proton at δH 7.37 (H-5) and the proton at  
δH 8.26 (H-6) showed a correlation with the proton at δH 8.78 (H-7). It confirmed the combination of 
the B, C and D rings, also implied carbonyl group was at position 1 not position 4. The methoxyl 
group at δH 4.09 (H-14) showed a NOE correlation with the proton at δH 6.89 (H-9). It indicated the 
combination of the A and B rings. 
In the COSY spectra, δH 10.10 (1H, s) and δH 8.78 (1H, s) there is no correlation with other protons, 
they connected with C-12 (δC 125.17), C-7 (δC 121.52), respectively. The full assignment of compound 1 
was supported by the HMBC correlations. The observed long range correlations from δH 1.46 (13-Me) 
to δC 145.61 (C-4a) and 198.76 (C-1) in the HMBC spectrum showed that a methyl group was attached 
to C-3, the HMBC correlation from δH 4.06 (OH, s) to δC 28.47 (C-13, 1-Me), 45.41 (C-4), 54.28 (C-2) 
and 70.55 (C-3) indicated that the hydroxyl group was attached to C-3. HMBC correlation from 
δH 4.09 (–O–CH3) to δC 155.38 (C-8) indicated that the methoxy group was attached to C-8. The Mar. Drugs 2011, 9  
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HMBC correlation from δH 3.35 (H-4), 7.37 (H-5) and 2.97 (H-2) to δC 198.76 (C-1) indicated that a 
carbonyl unit was in C-1. As shown in Figure 1B, the linkage of the Six-carbon ring with the 
anthracene skeleton was established by the correlations from δH 3.35 (H-4) and 2.97 (H-2) to δC 145.61 
(C-4a), δH 2.97 (H-2) to δC 125.46 (C-12b).  
Consequently, the structure of compound 1 was established to be 3-hydroxy-1-keto-3-methyl-8-
methoxy-1,2,3,4-tetrahydro-benz[α]anthracene (Table 1).  
2.2. Cytotoxicity and Antifungal Activities 
In the cytotoxicity test, compound 1  showed no cytotoxicity against human leukemic cells line  
HL-60 (Table 2), a weaker cytotoxicity against human hepatoma cell line BEL-7402 compared with 
adriamycin (Table 2). However, compound 1 exhibited a potent inhibitory activity against human lung 
adenocarcinoma cell line A549. Although compound 1 showed a weaker cytotoxicity at higher 
concentrations than the positive control, adriamycin, while at lower concentrations, the effect of 
compound 1 was found to be stronger than adriamycin (Table 2). 
Table 2. Cytotoxicity of compound 1 against human leukemic cells line HL-60, human 
hepatoma cell line BEL-7402, human lung adenocarcinoma cell line A549. 
Cancer cell line  Rate of inhibition of sample (%)
Concentration (M) 
10
−4 10
−5 10
−6 10
−7 10
−8 
human leukemic cells line HL-60  Rate of inhibition of compound 1 0  0  0  0  0 
Rate of inhibition of adriamycin  100  88.5  89.5  88.2  0 
human hepatoma cell line BEL-7402  Rate of inhibition of compound 1 37.5  37.0  25.7  19.5  0 
Rate of inhibition of adriamycin  80.9  85.7  63.4  32.8  15.5 
human lung adenocarcinoma cell line 
A549 
Rate of inhibition of compound 1 65.5  62.8  61.8  47.8  48.8 
Rate of inhibition of adriamycin  100  61.8  50.8  21.4  4.3 
The results demonstrated that the compound 1 almost showed no antifungal activities against the 
Monilinia fructicola (Mf) and Colletotrichum lagenarium (Cl) (Table 3). 
Table 3. Antifungal activity of compound 1. 
Microbial activities  The radius of the zone of inhibition (mm) 
Blank 6 
Antifungal (Mf)  8 
Antifungal (Cl)  9 
3. Experimental Section  
3.1. General Experimental Procedures  
NMR spectra were recorded on Bruker AVANCE III™ 500 spectrometers and TMS was used as 
internal standard. Column chromatography was carried out on silica gel (200–300 mesh) and Sephadex 
LH-20 (Amersham Biosciences, Uppsala, Sweden). LC-MS were obtained by ESI on a Thermo Fisher 
Scientific LCQ Fleet mass spectrometer. All reagents were of analytic grade. Mar. Drugs 2011, 9  
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Precoated silica gel plates (F-254, 0.2 mm) were used for analytical TLC. HPLC was performed on 
a JASCO PU-2087 HPLC apparatus with a Zorbax Eclipse XDB-C18 column (250 × 9.4 mm, 5 μm;  
2 mL/min; 254 nm; Agilent, Palo Alto, CA, USA). 
3.2. Strain and Medium for Isolation and Fermentation 
Marine Streptomyces sp. W007 isolated on Gause’s synthetic agar containing 50% natural seawater 
was from the marine sediments of Kiaochow Bay, Qingdao. Marine Streptomyces sp. W007 was 
characterized according to the 16S rRNA gene sequence (Accession No. JN180126 in GenBank). 
Monilinia fructicola (Mf) and Colletotrichum lagenarium (Cl) were from Qingdao Agricultural 
University (Shandong, China). 
Gause’s synthetic agar (for separation of streptomycete): soluble starch 20 g, KNO3 1 g, K2HPO4 
0.5 g, MgSO4·7H2O 0.5 g, FeSO4·7H2O 0.01 g, K2Cr2O7 0.3 g, seawater 500 mL, deionized water  
500 mL, pH 7.4. M2+ medium (for fermentation): malt extract 10 g, yeast extract 4 g, anhydrous 
glucose 4 g, deionized water 500 mL, seawater 500 mL, pH 7.8. 
3.3. Fermentation 
Well-grown agar cultures of Streptomyces sp. W007 were served to inoculate 1 L-Erlenmeyer flasks 
each containing 300 mL M2+ medium. The liquid medium of Streptomyces sp. W007 were incubated 
for 2 days with 180 rpm at 28 °C, then they were used to inoculate 100 Erlenmeyer flasks each 
containing 300 mL M2+ medium, inoculum size was 20% (v/v). At last, 100 Erlenmeyer flasks were 
held at 28 °C for 4 days (pH 7.8, 220 rpm). 
3.4. Extraction and Separation  
The culture broth (30 L) was filtered to give the mycelium and culture filtrate, and the filtrate was 
extracted by ethyl acetate. The mycelium was dried at 45 °С, and ultrasonically extracted three times 
by ethyl acetate and acetone respectively (15 min/time), then they were dried at 45 °С under reduced 
pressure. Three parts of organic layers were combined and defatted with cyclohexane to give a crude 
extract (8.4 g). The defatted extract was separated with silica gel column, five fractions were obtained. 
Fraction 1 was further purified by Sephadex LH-20 to afford A1–A5, A5 was purified by reverse 
column with a stepwise gradient of methanol/water (2:8–8:2) and detected by TLC to give four fractions 
(B1–B4). B4 was subjected to PTLC, during this step, three fractions (C1–C3) was obtained, C3 was 
separated by semi-preparative HPLC (JASCO PU-2087, Zorbax Eclipse XDB-C18, 250 × 9.4 mm; 
2 mL/min; 254 nm; Agilent, Palo Alto, CA, USA) eluting with CH3OH/H2O(80:20, v/v) to afford 
compound 1 (retention time 9.37 min, 12 mg). 
3.5. Cytotoxicity Tests and Antifungal Activities 
Cytotoxic activity was evaluated using the human leukemic cell line HL-60 by the MTT   
(Methyl-Thiazol-Tetrozolium) method [14] and the human lung adenocarcinoma cell line A549 and 
human hepatoma cell line BEL-7402 by the SRB (sulforhodamine B) method [15]. The antifungal Mar. Drugs 2011, 9  
 
 
1507
activities of compound 1 were evaluated using the agar diffusion assay [16]. Inhibition ratio was 
calculated according to the formula:  
sample
blank
sample
blank
A : the absorbance of the sample at 540/515;
A : the absorbance of the blank at 540/515.
A Inhibition ratio (1 ) 100% A =− ×
 
In the MTT assay, the cell line was grown in RPMI-1640 supplemented with 10% FBS (Fetal 
bovine serum) under a humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C. Cell suspensions 
(200 µL) at a density of 5 × 10
4 cells/mL were plated in 96-well microtiter plates and incubated for 
24 h. The compound 1 solutions (2 µL in MeOH) at different concentrations (0, 10
−4, 10
−5, 10
−6, 10
−7, 
10
−8 M) were added to each well and further incubated for 72 h under the same conditions. MTT 
solution (20 µL of a 5 mg/mL solution IPMI-1640 medium) was added to each well and incubated for 
4 h. RPMI-1640 medium (150 µL) containing MTT was then gently replaced by DMSO (dimethyl 
sulfoxide) and pipetted to dissolve any formazan crystals formed. Absorbance was then determined on 
a Spectra Max Plus plate reader at 540 nm. 
In the SRB assay, cell suspensions (200 µL) were plated in 96-cell plates at a density of   
2 × 10
5 cells/mL. Then compound 1 solutions (2 µL in MeOH) at different concentrations (0, 10
−4, 
10
−5, 10
−6, 10
−7, 10
−8 M) were added to each well and further incubated for 24 h. Following drug 
exposure, the cells were ﬁxed with 12% trichloroacetic acid and the cell layer was stained with   
0.4% SRB. The absorbance of SRB solution was measured at 515 nm. 
Agar diffusion assay: compound 1 was dissolved in MeOH/CH2Cl2 (1:1) at concentrations of   
5 µg/µL. Fifty microliters of each solution was pipetted onto a sterile filter disk, which was placed 
onto an appropriate agar growth medium for the respective test organism and subsequently sprayed 
with a suspension of the respective test organism. The disks (6 mm) were air-dried in bechtop, placed 
on an inoculated agar plate, and incubated at 28 °C overnight, the radius of the zone of inhibition was 
measured in mm. 
4. Conclusions 
The results of cytotoxic tests suggested that cytotoxicities of compound 1 are selective to the tested 
cell lines. Adriamycin plays an antitumor function: the interaction of adriamycin and type II DNA 
topoisomerase causes the DNA to break. Compound 1  showed a stronger cytotoxicity at low 
concentration, and weaker cytotoxicity at high concentration, than positive control adriamycin; such a 
phenomenon implied that antitumor mechanisms of adriamycin and compound 1  were different. 
Possible mechanisms for cytotoxic activity against human lung adenocarcinoma cell line A549 of 
compound 1 are as follows: compound 1 selectively induces apoptosis in human lung adenocarcinoma 
cell line A549 while sparing other cells; Compound 1 has negative effect on cancer cell proliferation 
and the cell cycle, maybe as an enzyme inhibitor; Compound 1 can inhibit metabolism of tumor cell 
lines and kill them.  
Therefore, further studies on the bioactivity of compound 1 are being carried out and the results 
described in this study suggest that compound 1 could potentially lead to antitumor agents. Mar. Drugs 2011, 9  
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